News
Media
Conferences
Partners
Publications
Events
CME/CE
Resources
PBM Directory
Commentaries
Subscribe

Spotlight -

Our June 2026 print issue|

Free Webinar: The Great 340B Debate|

2026 ASCO Annual Meeting|

2026 State of Pharmacy survey results available now

Opinion|Videos|September 12, 2024

Investigational Agents for Idiopathic and Progressive Pulmonary Fibrosis

Author(s)Paul Frohna, MD, PhD

Dr Frohna discusses some therapies under investigation for idiopathic and progressive pulmonary fibrosis, including one targeting the PDE4 pathway.

Episodes in this series

EP. 1 Symptoms, Manifestations and Mortality Rate of IPF

EP. 1 Symptoms, Manifestations and Mortality Rate of IPF

EP. 2 How the GAP Program Helps Determine Patient Prognosis, and Risk Factors for Developing IPF/PPF

EP. 2 How the GAP Program Helps Determine Patient Prognosis, and Risk Factors for Developing IPF/PPF

EP. 3 Epidemiology Facts, Differential Diagnosis, and Arriving at a IPF or PPF Diagnosis

EP. 3 Epidemiology Facts, Differential Diagnosis, and Arriving at a IPF or PPF Diagnosis

EP. 4 Critical Early Diagnoses and Acute Exacerbations in IPF and PPF

EP. 4 Critical Early Diagnoses and Acute Exacerbations in IPF and PPF

1 KOL is featured in this series.

EP. 5 Exploring the Role of Non-Pharmacological Modalities and Multidisciplinary Care in Patients with Idiopathic and Progressive Pulmonary Fibrosis

1 KOL is featured in this series.

EP. 6 Managing Acute Exacerbations and the Psychosocial Aspect of Idiopathic and Progressive Pulmonary Fibrosis

1 KOL is featured in this series.

EP. 7 Key Unmet Needs Associated with Idiopathic and Progressive Pulmonary Fibrosis

EP. 8 The Roles of Biomarker Testing and HRCT in IPF and PPF

EP. 8 The Roles of Biomarker Testing and HRCT in IPF and PPF

EP. 9 Unmet Needs and the Role of AI in Earlier Disease Detection

EP. 9 Unmet Needs and the Role of AI in Earlier Disease Detection

1 KOL is featured in this series.

EP. 10 Adverse Events Associated with Anti-Fibrotic Therapies

1 KOL is featured in this series.

EP. 11 Investigational Agents for Idiopathic and Progressive Pulmonary Fibrosis

1 KOL is featured in this series.

EP. 12 The Future of Idiopathic and Progressive Pulmonary Fibrosis Treatment

EP. 13 K-Cast Written Summary. Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis

EP. 13 K-Cast Written Summary. Exploring Key Unmet Needs in Idiopathic Pulmonary Fibrosis

What are some of the pharmacotherapies being investigated in phase 3 clinical trials for IPF/PPF, and what have the data shown thus far?

Phosphodiesterase (PDE) 4 inhibition is currently being investigated in IPF/PPF. What is the rationale for studying this pathway?

Newsletter

Get the latest industry news, event updates and more from Managed Healthcare Executive.

Related Content

Key Takeaways, Study Limitations, and the Broader Implications of CROWN for Patients, Providers, and Payers

ByChristine Lovly, MD, PhD,Alice Shaw, MD, PhD

July 3rd 2026

From Clinical Trials to Community Practice: Contextualizing Lorlatinib's Durability and Implementing Long-Term Management Strategies

ByChristine Lovly, MD, PhD,Alice Shaw, MD, PhD

June 26th 2026

Managing Lorlatinib's Unique Safety Profile: Dose Optimization and Practical Strategies for Long-Term Tolerability

ByChristine Lovly, MD, PhD,Alice Shaw, MD, PhD

June 26th 2026

Interpreting CROWN's Key Efficacy Outcomes: PFS Milestones, Survival Probabilities, and the Overall Survival Story

ByChristine Lovly, MD, PhD,Alice Shaw, MD, PhD

June 19th 2026

The CROWN Study: Design, Context, and the Clinical Significance of 7-Year Follow-Up Data

ByChristine Lovly, MD, PhD,Alice Shaw, MD, PhD

June 19th 2026

Latest CME

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Jacob Sands, MD; Jennifer Carlisle, MD; Hossein Borghaei, DO, MS

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Benjamin P. Levy, MD; Ticiana Leal, MD; Aaron Lisberg, MD; Christine M. Lovly, MD, PhD, FASCO

Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors

Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors

July 14, 2026

27th Annual International Lung Cancer Congress®

In-Person Event

27th Annual International Lung Cancer Congress®

July 24-25, 2026

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO; Maurice Pérol, MD

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

Solange Peters, MD, PhD; Myung-Ju Ahn, MD, PhD; Luis Paz-Ares, MD, PhD; Jacob Sands, MD

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

Solange Peters, MD, PhD; Stephanie McDonald, FNP-BC, AOCNP; Antonio Passaro, MD, PhD; Jacob Sands, MD

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Jonathan Goldman, MD; Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Ignacio I. Wistuba, MD

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

26th Annual International Lung Cancer Congress

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Jacob Sands, MD; Anne Chiang, MD, PhD

20th Annual New York Lung Cancers Symposium®

20th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Jamie Chaft, MD

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on Managed Healthcare Executive

Vitiligo is associated with mental heath conditions, other autoimmune diseases

Centanafadine hits primary and key secondary endpoints in ADHD phase 3b trial

A conversation about vaccines and monoclonal antibodies with Marc Elia, Chairman of Invivyd’s Board of Directors

Modernizing Pharmacy Benefit Administration: Addressing Legacy System Friction for Health Plans

Make lab monitoring of patents taking isotretinoin less routine, more based on symptoms